Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
US6368602B1 · kind B1 · utility
4Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2000 |
| Grant date | Apr 9, 2002 |
| Priority date | — |
| Expiry date | Jun 16, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/32461
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for administering the HAV vaccine to a subject by absorption through a mucosal tissue, particularly through the mucosa of the rectum. The method of the present invention enables the HAV vaccine to be administered to the subject rectally, for example as a suppository or other rectal dosage form, and to successfully immunize the subject against HAV. Thus, the present invention overcomes problems of background art methods of administration, such as systemic administration by injection for example, which require needles, and which are difficult and expensive to perform.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.